Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 15;73(2):352-353.
doi: 10.1093/cid/ciaa1390.

Response to Jia and Wang

Xu Liu  1   2 , Qi Liu  1   3 , Xueting Yao  1 , Miao Zhang  1 , Cheng Cui  1 , Haiyan Li  1 , Dongyang Liu  1
Affiliations
Editorial

Response to Jia and Wang

Xu Liu et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Jia R , Wang H. How could in vitro antiviral activity be applied to optimize the dosing regimens of candidates for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)? Clin Infect Dis 2020; ciaa1325. doi:10.1093/cid/ciaa1325 - DOI - PMC - PubMed
    1. Yao X , Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71:732–9. - PMC - PubMed
    1. Liu X , Chen H, Shang Y. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020; 21:622. - PMC - PubMed
    1. Huang M , Tang T, Pang P, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol 2020; 12:322–5. - PMC - PubMed
    1. Huang M , Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci Rev 2020; doi:10.1093/nsr/nwaa113 - DOI - PMC - PubMed